EQS-News: Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
|
EQS-News: Viromed Medical AG
/ Key word(s): Miscellaneous
PRESS RELEASE Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology Rellingen, March 23, 2026 – Viromed Medical AG (“Viromed“; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has received funding approval from the Federal Ministry of Research, Technology and Space for research and development projects in the field of cold plasma technology. The certification was granted under the Research Allowance Act (FZulG) and comprises funding in the high six-figure euro range. The funding focuses, among other things, on the further development of innovative medical systems for the application of cold atmospheric plasma, including a stationary system for integration into ventilation processes (PulmoPlas®). The aim is to selectively inactivate pathogenic germs in the lower respiratory tract and thereby enable new therapeutic approaches, particularly in intensive care medicine. In addition, the development of a mobile device for contact-free plasma application to support wound healing (ViroCap®) is being funded. Both projects address key medical challenges and expand the current state of the art. The funding underscores Viromed’s strong innovative capabilities and confirms the scientific and technological relevance of its solutions. In particular, the application of cold plasma in the lungs represents a novel approach for which no comparable systems currently exist. With this funding, Viromed is consistently advancing the development of PulmoPlas® and ViroCap® and strengthening its position in the field of non-pharmacological treatment of infectious diseases.
About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential. www.viromed-medical-ag.de
Contact Viromed E-Mail: kontakt@viromed-medical.de
Press contact E-Mail: viromed@kirchhoff.de
23.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| EQS News ID: | 2295936 |
| End of News | EQS News Service |
|
|
2295936 23.03.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,37 | 9,00 | 80,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,50 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 5,56 | 10,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,02 | 0,04 | 0,07 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 136,69 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 51,92 | 0,00 | 0,00 | 337,50 | 6,84 | -1.242,61 | 99,77 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 30.09.2024 | 30.06.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +9,83% | +49,50% | +89,47% | +51,26% | +50,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
